Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

BOTHELL, Wash., Aug. 7 /PRNewswire-FirstCall/ -- SCOLR Pharma, Inc. (NYSE Amex: DDD) today reported financial results for the three and six months ended June 30, 2009.

Dr. Bruce Morra, SCOLR Pharma's President and CEO, said, "We continue to advance discussions with a number of potential partners for our 12-hour controlled release ibuprofen. These potential partners have been committing resources to due diligence and preliminary negotiations of license terms. In the nutraceutical arena, we are working with companies interested in commercializing products we have developed for growing segments of this field in both the US and international markets. We continue to work with our investment bankers on potential strategic transactions, including mergers and other business combinations that could yield opportunities to increase shareholder value and provide additional resources for us to develop our Controlled Delivery Technology (CDT(R)) platforms. However, we are faced with a difficult marketplace and many specialty pharmaceutical companies competing for alliances with the more established pharmaceutical and consumer product companies. Our operating strategy is to preserve our capital by limiting clinical and development expenses to our ibuprofen and pseudoephedrine lead products while also supporting our existing alliances. We have made significant reductions to our operating expenses so far this year and are continuing to evaluate additional areas to further minimize our burn rate."

Total revenues, which consist of royalty revenue from our collaboration agreements, decreased 17%, or $48,782 to $230,789 for the three months ended June 30, 2009, compared to $279,571 for the same period in 2008. This decrease is primarily due to lower royalty income from our relationship with Perrigo.

Royalt
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... Typical racks for laboratory freezers are generally ... often taking up unnecessary room in already crowded freezers. ... Box Freezer Racks offer a customizable storage solution ... boxes and freezers. , “These racks are perfect ... multiple people because users can configure freezer space to ...
(Date:6/3/2015)... Green Earth Energy has restructured their ... the RCBC Waste to Energy system. Paul Douglas ... family business, http://www.greenearthwaste.com which has been operating ... recycling to their waste collection services in 2012 and ... Fortune 500 companies with manufacturing plants in West Tennessee. ...
(Date:6/3/2015)... REYKJAVIK, Iceland , June 3, 2015   ... genome to improve health worldwide, today announced that it ... to provide clinical interpretation of the whole genome sequences ... of the first phase of the 100,000 Genomes Project ... WuXi NextCODE will deploy its unique database ...
(Date:6/3/2015)... June 03, 2015 Global Stem ... Inc. have announced plans to conduct Romania’s first ever ... Through an alliance with Miami-based Stem Cell Training, Inc., ... the Adipose and Bone Marrow Stem Cell Training Course ... reconstructive plastic surgery specialist practicing in Bucharest and Tel ...
Breaking Biology Technology:Freezer Space Can Now Be Configured Your Way with New Modular Freezer Racks 2WuXi NextCODE Wins Genomics England Clinical Interpretation Tender in both Rare Disease and Cancer 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 2Global Stem Cells Group Announces First Stem Cell Training Course to Take Place in Romania 3
... Jersey, October 29, Rosetta Genomics Ltd. (Nasdaq: ROSG ... announced today its,management will present at Oppenheimer 19th ... the Waldorf-Astoria Hotel in New York,City., About ... occurring, small,RNAs that act as master regulators and ...
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a vaccine-focused ... scheduled to present at two upcoming investor conferences, ... York City and the,Credit Suisse Asian Healthcare Conference ... Financial Manager, is scheduled to present on,Tuesday, November ...
... Osteotech, Inc.,(Nasdaq: OSTE ), a leader ... healing, announced today that it has received 510(k) ... ("FDA") for its next,generation grafting material. Osteotech received ... substitute, and as a bone void filler, for ...
Cached Biology Technology:Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 2Rosetta Genomics to Present at Oppenheimer's 19th Annual Healthcare Conference 3Sinovac to Participate in Two Upcoming Investor Conferences 2Osteotech Receives FDA Clearance for its Next Generation Grafting Material 2
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/20/2015)... OXFORD, Conn. , May 20, 2015 ... "Company") announces that its wholly owned subsidiary, 3D-ID LLC, ... contractor under Team Battelle for the biometrics technology portion ... Unrestricted Suite Contract from the Department of the Army. ... facial recognition products developed for government, law enforcement and ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Francisco have launched a groundbreaking study to determine whether ... the most common congenital chest deformity, in the same ... chest, which is known medically as pectus excavatum, is ... to the breastbone. The deformed cartilage pulls the breastbone ...
... recurrent cancer of the central nervous system that occurs primarily ... a clinical trial at the University of California, San Francisco. ... is always fatal. Findings from a group of 12 ... effective in stimulating the patient’s immune system to attack ...
... that chimpanzees from West Africa were cracking nuts with ... years ago. The result suggests chimpanzees developed this behaviour ... was a trait inherited from our common ancestor. Julio ... the Noulo site in Cote d'Ivoire, the only known ...
Cached Biology News:Study to explore using magnets to correct 'sunken chest' 2Study to explore using magnets to correct 'sunken chest' 3UCSF brain tumor vaccine trial shows promising results 2UCSF brain tumor vaccine trial shows promising results 3The chimpanzee stone age 2